OncLive

Everolimus Reduces Breast Cancer Effects in Bone
Ob.Gyn. News Digital Network
Adding everolimus to exemestane for the treatment of estrogen receptor–positive advanced breast cancer that is refractory to nonsteroidal aromatase inhibitors has beneficial effects on bone turnover and breast cancer progression in bone, according to ...
Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast CancerOncLive
Novartis launches breast cancer drug Afinitor in UKZenopa
Afinitor's new UK indication launchedInPharm
GenomeWeb
all 11 news articles »